We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fast Diagnostic Tool Investigated for Wound Infections

By LabMedica International staff writers
Posted on 29 Aug 2011
A novel concept for a fast diagnostic tool for wound infection based on enzymes triggered release of dye from a polymeric matrix has been investigated.

For the development of a simple diagnostic tool, a liquid lysozyme assay was adapted to a solid system and the matrix consisted of alginate/agarose and peptidoglycan covalently labeled with Remazol brilliant blue. More...


Scientists from the Graz University of Technology (Austria) collected wound fluid from 10 postoperative wounds, 8 decubitus ulcer wounds, and 8 blisters and analyzed by biochemical techniques. The detection of wound infection was based on lysozyme and elastase triggered release of the dye from a peptidoglycan matrix. Incubation of 8% labeled agarose/peptidoglycan blend layers with infected wound fluid samples for two hours at 37 °C resulted in a four-fold higher amount of dye released than measured for noninfected wounds. Lysozyme activity in postoperative wounds and decubitus (bed sore) wound fluids was significantly elevated upon infection (4,830 ± 1,848 U/mL), compared to noninfected wounds (376 ± 240 U/mL).

A seven-fold higher amount of dye was released in case of infected wound fluid samples compared to noninfected ones using an alginate/peptidoglycan beads assay. By using Western blotting techniques, proteases including the gelatinase matrix metalloproteinases MMP-2 and MMP-9, and elastase were detected in wound fluids. A slight synergistic effect was measured by dye release for peptidoglycan hydrolysis, between lysozyme and these proteases. Incubation of a double-layer system consisting of stained and nonstained peptidoglycan with infected wound fluids resulted in a color change from yellow to blue, thus allowing simple visual detection of wound infection.

The authors concluded that such a diagnostic tool would allow early intervention with suitable treatment and could reduce clinical intervention and the use of antibiotics. The tool is based on human enzymes, which can be detected in wound fluid samples in a very fast way and which were shown to be elevated in case of infection. The study was published in September 2011, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Graz University of Technology





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.